CDK

Actions
  1. Inhibitor (36)


Items 1 to 25 of 38 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Application Product Information
A15485

AG-024322

CDK inhibitor
AG-24322 is a second generation CDK inhibitor. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models.
A14025

AMG-925

Dual FLT3/CDK4 inhibitor
AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.
A10093

AT7519

CDK Inhibitor
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation.
A11313

AT7519 HCl

CDK inhibitor
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation.
A15005

AT7519 trifluoroacetate

CDK inhibitor
AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM, less potent to CDK3 and little active to CDK7.
A11105

AZD5438

CDK inhibitor
AZD5438 is a potent inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 (IC50 values are 16, 6 and 20 nM respectively).
A12742

BAY 1000394 (Roniciclib)

CDK inhibitor
BAY 1000394 is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
A11154

BMS-265246

CDK inhibitor
BMS-265246 is a potent new pyra- zolopyridine inhibitor of cdk2/cyclin E and cdk1/cyclin B, as well as cdk4/cyclin D.
A13677

BMS-863233 (XL-413)

CDK inhibitor
BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
A10163

BS-181 HCl

CDK inhibitor
BS-181 HCl is a potential anti-tumor agent as CDK7 inhibitor.
A11347

CGP60474

CDK Inhibitor
CGP60474 is a potent inhibitor of cyclin-dependent kinase (CDK).
A15054

CVT-313

CDK2 Inhibitor
CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).
A11129

Dinaciclib (SCH 727965)

CDK Inhibitor
Dinaciclib (SCH 727965) is a potent and selective cyclin-dependent kinase (CDK) inhibitor, selectively inhibiting CDK1, CDK2, CDK5 and CDK9 with IC50 values of 3, 1, 1 and 4 nM respectively.
A10390

Flavopiridol (Alvocidib)

CDK inhibitor
Flavopiridol (Alvocidib) is a cyclin-dependent kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia.
A11045

Flavopiridol HCl

CDK inhibitor
Flavopiridol HCl is an inhibitor of cyclin-dependent kinases. The (-)-cis form induces apoptosis in particular tumor cells.
A10471

Indirubin

CDK inhibitor
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.
A10494

JNJ-7706621

Aurora Inhibitor
JNJ-7706621 is a novel cell cycle inhibitor that showed potent inhibition of several cyclin-dependent kinases (CDK) and Aurora kinases.
A11220

Kenpaullone

CDK inhibitor
Kenpaullone is a potent inhibitor of CDK1/cyclin B (IC₅₀ = 400 nM), CDK2/cyclin A (IC₅₀ = 680nM) , CDK5 (IC₅₀ = 850nM) and with much less effect other kinases.
A14273

LDC000067

CDK inhibitor
LDC000067 is a highly selective CDK9 inhibitor .
A13549

LEE011 (Ribociclib)

CDK4/6 inhibitor
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
A12989

LY2835219

-
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
A15823

LY2857785

CDK9 inhibitor
LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.
A12438

NU 6102

CDK inhibitor
NU6102 is selective for CDK1 and CDK2 compared to CDK4/D1 (IC50=1.6 μM), DYRK1A (IC50=0.9 μM), PDK1 (IC50=0.8 μM) and ROCKII (IC50=0.6 μM).
A15767

NU2058

CDK inhibitor
NU2058 is a guanine-based CDK inhibitor with IC50 of 17 uM and 26 uM for CDK2 and CDK1.
A15196

NVP-LCQ195

CDK inhibitor
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.

Items 1 to 25 of 38 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction